Structured population data were available for 6 of 6 supporting studies. 3 studies described participants with type 2 diabetes. 5 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

3 of 6 studies with duration data have follow-up of 12 weeks or less.

Metformin

Core clinician-reference fields are available or not applicable.

Patients received up to 100 mg of acarbose, three times per day.

Acarbose Group

Finally, a total of 551 participants (286 in the acarbose group and 265 in the metformin group) were included in this study.

Patients received sustained-released metformin hydrochloride up to 1,500 mg, one time per day.

Metformin Group

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Metformin and acarbose improve glycemic control in type 2 diabetes

Placebo

Participants received metformin for 3 months followed by a washout period and then switched to placebo for another 3 months.

Participants were randomly assigned in a 1:1 ratio to receive either metformin or placebo for 3 months. Then, after a 1-month washout period (116 half-lives for metformin), the medication was changed to the other treatment for another 3 months.

Participants received placebo for 3 months followed by a washout period and then switched to metformin for another 3 months.

Metformin improves glycemic control in heart failure patients

Insulin group

Participants received metformin starting at 500 mg once a day, increased to meet glycemic targets.

Metformin group

Participants were randomized into metformin and insulin treatment groups. Starting dose of metformin was 500 mg once a day and increased gradually over two (2) weeks, to meet glycemic targets.

Participants received insulin, starting dose calculated as 0.3 IU/kg body weight, titrated to achieve glycemic control.

Insulin was added if targets could not be reached on metformin alone at maximum doses. Total daily dose of premixed insulin at initiation was calculated as 0.3 IU/kg body weight and titrated upwards to achieve glycemic control.

Metformin is more effective than insulin for glycemic control in pregnancy

Not extracted from the authoritative source.

Available source content was suppressed because validation identified a conflict.

Clinician-reference record is usable with limitations in: comparator.

Control group receiving metformin tablets daily for 45 days.

Group A (Control)

In Group A (Control), metformin tablets (500 mg) will be prescribed daily once before lunch with plain water for 45 consecutive days.

Interventional group receiving Nimba-Amalakyadi formulation twice daily for 45 days.

Group B (Interventional group)

In Group B (Interventional group), the Nimba-Amalakyadi formulation will be prescribed 5 grams twice daily with an empty stomach (ie, 7 AM-5 PM) with lukewarm water for 45 consecutive days.

Nimba Amalakyadi Improves Glycemic Control in Type 2 Diabetes

Postmeal Metformin Group

Participants received metformin before meals for 4 weeks.

Premeal Metformin Group

All participants were randomly assigned to receive immediate-release metformin either 30–60 min before or immediately after meal for 4 weeks.

Participants received metformin after meals for 4 weeks.

Premeal metformin improves postmeal glucose control in diabetes.

Not reported in the authoritative source.

Clinician-reference record is usable with limitations in: design, comparator, risk_of_bias.

Patients receiving metformin as monotherapy.

Metformin group (Group M)

Patients receiving metformin 1000 mg once daily were taken in Group M.

Patients receiving metformin plus ranolazine.

Metformin plus ranolazine group (Group M+R)

Patients receiving metformin 1000 mg once daily plus ranolazine were enrolled in Group M+R.

Authoritative quality diagnostic: authoritative design unavailable.

Metformin × Glucose iAUC (OGTT)

Available supporting studies

Metformin and acarbose improve glycemic control in type 2 diabetes

Metformin improves glycemic control in heart failure patients

Metformin is more effective than insulin for glycemic control in pregnancy

Nimba Amalakyadi Improves Glycemic Control in Type 2 Diabetes

Premeal metformin improves postmeal glucose control in diabetes.

Ranolazine improves glycaemic control when added to metformin in T2DM patients